Neogenomics (NEO) Shares Outstanding (Diluted Average) (2011 - 2026)

Neogenomics has reported Shares Outstanding (Diluted Average) for 15 years, with the latest figure at $129.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 1.41% year-over-year to $129.2 million; the trailing twelve-month figure through Mar 2026 stood at $129.2 million (up 1.41% YoY), and the FY2025 full-year result was $128.1 million, up 1.14% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $129.2 million, up from $128.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $129.2 million in Q1 2026, with the low at $123.6 million in Q1 2022.
• Historically, Shares Outstanding (Diluted Average) has averaged $126.1 million across 5 years, with a median of $126.1 million in 2024.
• The largest YoY upside for Shares Outstanding (Diluted Average) was 6.4% in 2022 against a maximum downside of 5.46% in 2022.
• Neogenomics' Shares Outstanding (Diluted Average) stood at $124.2 million in 2022, then advanced by 1.03% to $125.5 million in 2023, then increased by 0.92% to $126.7 million in 2024, then grew by 1.14% to $128.1 million in 2025, then rose by 0.83% to $129.2 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $129.2 million (Q1 2026), $128.1 million (Q4 2025), and $127.9 million (Q3 2025), per Business Quant data.